b'1 PRESCRIBED BRAND IN THE In adult patients with T2D and establishedFor the Ozempic CVOT primary endpoint, when added to standard of care 1,d95# aGLP-1 RA CLASS WORLDWIDEFOR PATIENTS WITH T2Db Ozempic had a 26% RRR of MACE 1CVD, for the composite primary endpoint 1,b,c(2.3% ARR at 109 weeks)After 2 years Time to first confirmed major adverse CV event (MACE) 1,2,cOzempic10 Hazard ratio, 0.74 8.9 %(95% CI; 0.58-0.95).Standard of caresignificantly 8 P 0.001 for noninferiority vs Baseline: (n=146 of 1649)Patients with MACE (%)placebo plus standard of care.reduced the 6 P =0.02 for superiority, not prespecified. NNT1 * 4 6.6 % 45risk of MACE ,c Ozempic 0.5 mg and Number needed 1 mg + standard of careBaseline: (n=108 of 1648) to treat to *prevent 1 MACE Composite MACE endpoint:2 (2 years 1,3,e ) 2CV death, nonfatal MI, or nonfatal stroke. 1 00 8 16 24 32 40 48 56 64 72 80 88 96 104 109Weeks since randomizationComposite MACE endpoint: CV death, nonfatal MI, or nonfatal strokeSUSTAIN 6: Cardiovascular outcomes1 a Source: Based on internal analysis by Novo Nordisk using data from the following source: IQVIA Monthly MIDAS database, Measure: Volume sales, ATC3 A10S, for the Study design: 2-year, randomized, multicenter, multinational, placebo-controlled, double-blind cardiovascular outcomes trial designed to assess noninferiority time period MAT 09.2022 reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.bComposite MACE endpoint in SUSTAIN 6 included: CV death, nonfatal MI, or nonfatal stroke.1of Ozempic 0.5 mg and 1 mg vs placebo, both in addition to standard of care, for time to first MACE using a risk margin of 1.3. c Patients: A total of 3297 adult patients with inadequately controlled type 2 diabetes and atherosclerotic cardiovascular disease were randomized to once- d Results apply to Ozempic0.5 mg and 1 mg plus standard of care vs placebo plus standard of care.Standards of care included, but were not limited to, oral antidiabetic treatments, insulin, antihypertensives, diuretics, lipid-lowering therapies, and antithrombotic medications.weekly Ozempic0.5 mg (n=826), Ozempic1 mg (n=822), or placebo (n=1649), all in addition to standard of care treatments for diabetes and CVD such eEstimated cumulative risk of MACE at Week 104 was 6.2% with Ozempic 0.5 mg and 1 mg and 8.4% with placebo.as oral antidiabetic treatments, insulin, antihypertensives, diuretics, lipid-lowering therapies, and antithrombotic medications at investigator discretion.Primary composite endpoint: Time from randomization to first occurrence of a 3-part composite MACE, defined as CV death, nonfatal MI, or nonfatal stroke.GLP-1 RA=glucagon-like peptide-1 receptor agonist; T2D=type 2 diabetes; CVD=cardiovascular disease; CV=cardiovascular; MI=myocardial infarction; Indications and Limitations of Use CVOT=cardiovascular outcomes trial; RRR=relative risk reduction; ARR=absolute risk reduction; CI=confidence interval.Ozempic (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults withImportant Safety Information Acute Gallbladder Disease: Acute events of gallbladder disease type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, or nonfatalsuch as cholelithiasis or cholecystitis have been reported in GLP-1 stroke) in adults with type 2 diabetes mellitus and established CV disease.Warnings and Precautions receptor agonist trials and postmarketing. In placebo-controlled trials, Ozempic has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. Never Share an Ozempic Pen Between Patients: Ozempic penscholelithiasis was reported in 1.5% and 0.4% of patients treated Ozempic is not indicated for use in patients with type 1 diabetes mellitus. must never be shared between patients, even if the needle is changed.with Ozempic 0.5 mg and 1 mg, respectively, and not reported in Important Safety Information Pen-sharing poses a risk for transmission of blood-borne pathogens. placebo-treated patients. If cholelithiasis is suspected, gallbladder in combination with anstudies and appropriate clinical follow-up are indicated.Hypoglycemia: Patients receiving OzempicWARNING: RISK OF THYROID C-CELL TUMORS insulin secretagogue (eg, sulfonylurea) or insulin may have an increasedAdverse ReactionsIn rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevantrisk of hypoglycemia, including severe hypoglycemia. Inform patientsThe most common adverse reactions, reported in 5% of patients exposures. It is unknown whether Ozempiccauses thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humansusing these concomitant medications of the risk of hypoglycemia andtreated with Ozempic are nausea, vomiting, diarrhea, abdominal as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. educate them on the signs and symptoms of hypoglycemia. pain, and constipation.Ozempic is contraindicated in patients with a personal or family history of MTC and in patients with Multiple EndocrineAcute Kidney Injury: There have been postmarketing reports of Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Ozempic and informacute kidney injury and worsening of chronic renal failure, whichDrug Interactionsthem of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring ofmay sometimes require hemodialysis, in patients treated with GLP-1When initiating Ozempic, consider reducing the dose of concomitantly serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Ozempic. receptor agonists. Some of these events have been reported inadministered insulin secretagogue (such as sulfonylureas) or insulin to patients without known underlying renal disease. A majority of thereduce the risk of hypoglycemia.Contraindications reported events occurred in patients who had experienced nausea,Ozempic causes a delay of gastric emptying and has the potential to Ozempic is contraindicated in patients with a personal or family historyPancreatitis: Acute and chronic pancreatitis have been reported in clinicalvomiting, diarrhea, or dehydration. Monitor renal function whenimpact the absorption of concomitantly administered oral medications, of MTC or in patients with MEN 2, and in patients with a hypersensitivitystudies. Observe patients carefully for signs and symptoms of pancreatitis initiating or escalating doses of Ozempic in patients reporting severeso caution should be exercised.reaction to semaglutide or to any of the excipients in Ozempic. Serious(persistent severe abdominal pain, sometimes radiating to the back with adverse gastrointestinal reactions.hypersensitivity reactions including anaphylaxis and angioedema haveor without vomiting). If pancreatitis is suspected, discontinue OzempicHypersensitivity: Serious hypersensitivity reactions (eg, anaphylaxis,Use in Specific Populationsbeen reported with Ozempic.promptly, and if pancreatitis is confirmed, do not restart. angioedema) have been reported in patients treated with Ozempic.There are limited data with semaglutide use in pregnant women to If hypersensitivity reactions occur, discontinue use of Ozempic; treatinform a drug-associated risk for adverse developmental outcomes. Warnings and Precautions Diabetic Retinopathy Complications: In a 2-year trial involvingpromptly per standard of care, and monitor until signs and symptomsDiscontinue Ozempic in women at least 2 months before a planned Risk of Thyroid C-Cell Tumors: Patients should be referred to anpatients with type 2 diabetes and high cardiovascular risk, more eventsresolve. Use caution in a patient with a history of angioedema orpregnancy due to the long washout period for semaglutide.of diabetic retinopathy complications occurred in patients treated endocrinologist for further evaluation if serum calcitonin is measured with Ozempic (3.0%) compared with placebo (1.8%). The absoluteanaphylaxis with another GLP-1 receptor agonist.Please see Brief Summary of Prescribing Information on following pages.and found to be elevated or thyroid nodules are noted on physicalrisk increase for diabetic retinopathy complications was larger among examination or neck imaging. patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complicationsFor additional information, please has not been studied. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. follow our HCP site at OzempicPro.com.Ozempic is a registered trademark of Novo Nordisk A/S. References: 1. Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk; 2022. 2. Marso SP, Bain SC, Consoli A, et al; Novo Nordisk is a registered trademark of Novo Nordisk A/S. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med.2023 Novo NordiskPrinted in the U.S.A.US23OZM00147March 2023 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141 3. Data on file. Novo Nordisk Inc; Plainsboro, NJ.'